The use of biologicals in cutaneous allergies - Present and future

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 5, 2014, Pages 409-416

  Makris, Michael P ^a,b,c   Papadavid, Evangelia ^b   Zuberbier, Torsten ^c  

^a Allergy Unit 'D Kalogeromitros'   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

atopic dermatitis; chronic urticaria; omalizumab; rituximab; TNF antagonist

Indexed keywords

BIOLOGICAL PRODUCT; IMMUNOGLOBULIN E; MEPOLIZUMAB; OMALIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ASTHMA; ATOPIC DERMATITIS; CHRONIC URTICARIA; DRUG APPROVAL; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; REVIEW; SKIN ALLERGY; ANIMAL; ANTAGONISTS AND INHIBITORS; ASTHMA; BIOLOGICAL THERAPY; DERMATITIS, ATOPIC; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; PERSONALIZED MEDICINE; SKIN; URTICARIA;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ASTHMA; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; DERMATITIS, ATOPIC; DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; SKIN; TUMOR NECROSIS FACTOR-ALPHA; URTICARIA;

EID: 84906938483     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000096     Document Type: Review

References (66)

1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69:868-887.
2. Greaves MW, Tan KT. Chronic urticaria: recent advances. Clin Rev Allergy Immunol 2007; 33:134-143.
3. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197-201.
4. Konstantinou GN, Asero R, Ferrer M, et al. EAACI task force position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013; 68:27-36.
5. Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol 2008; 20:709-716.
6. Bernstein JA, Lang DM, Khan DA. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014; 133:1270-1277.
7. Asero R, Tedeschi A, Cugno M. Treatment of Chronic Urticaria. Immunol Allergy Clin N Am 2014; 34:105-116.
8. Babu KS, Polosa R, Morjaria JB. Anti-IgE-emerging opportunities for omalizumab. Expert Opin Biol Ther 2013; 13:765-777.
9. Eckman JA, Sterba PM, Kelly D, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010; 125:889-895.
10. Zaidi AK, Saini SS, Macglashan DW Jr. Regulation of Syk kinase and FcRb expression in human basophils during treatment with omalizumab. J Allergy Clin Immunol 2010; 125:902-908; e7.
11. MacGlashan DW Jr, Savage J, Wood RA, et al. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on two competing factors. J Allergy Clin Immunol 2012; 130:1130-1135.
12. Macglashan DW, Saini SS. Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin Immunol 2013; 132:906-911.
13. Young-Hee N, Joo-Hee K, Hyun Jung J, et al. Effects of omalizumab treatment in patients with refractory chronic urticaria. Allergy Asthma Immunol Res 2012; 4:357-361.
14. Buyukozturk S, Gelincik A, Demirturk M, et al. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol 2012; 39:439-442.
15. Groffik A, Mizel-Kaoukhov H, Magerl M, et al. Omalizumab: an effective and safe treatment of therapy resistant chronic spontaneous urticaria. Allergy 2011; 66:303-305.
16. Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol 2010; 90:443-444.
17. Metz M, Ohanyan T, Church MK, et al. Omalizumab is an effective and rapidly acting therapy in difficult to treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci 2014; 73:57-62.
18. Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. Allergy Asthma Proc 2013; 34:446-452.
19. Song CH, Stern S, Giruparajah M, et al. Long-term efficacy of fixed dose omalizumab for patients with severe chronic spontaneous urticaria. Ann Allergy Asthma Immunol 2013; 110:113-117.
20. Sussman G, Hebert J, Barron C, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol 2014; 112:170-174.
21. Altman M, Naimi D. Omalizumab for chronic urticaria [letter]. N Engl J Med 2013; 368:2528-2530.
22. Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122:569-573.
23. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose ranging study of single-dose omalizumab in patients with H1-antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128:567-573.
24. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128:202-209.
25. Maurer M, Rosen K, Hsin-Ju HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013; 368:924-935.
26. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaenous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132:101-109.
27. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res 2012; 4:326-331.
28. Uysal P, Eller E, Mortz CG, et al. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individalized. J Allergy Clin Immunol 2014; 133:914-915.
29. Metz M, Ohanyan T, Church MK, et al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014; 150:288-290.
30. Abajian M, Mlynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep 2012; 12:281-287.
31. Metz M, Bergmann P, Zuberbier T, et al. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63:247-249.
32. Brodska P, Schmid-Grendelmeier P. Treatment of severe cold contact urticaria with omalizumab: case reports. Case Rep Dermatol 2012; 4:275-280.
33. Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010; 65:130-139.
34. Krause K, Ardelean E, Kessler B, et al. Antihistamine resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy 2010; 65:1494-1495.
35. Guzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008; 63:1563-1565.
36. Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol 2009; 35:e127-e129.
37. Hauser SL, Waubant E, Arnold DL, et al., HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358:676-688.
38. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357:545-552.
39. Arkwright PD. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. J Allergy Clin Immunol 2009; 123:510-511.
40. Chakravarty SD, Yee AF, Paget SA. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. J Allergy Clin Immunol 2011; 128:1354-1355.
41. Mallipeddi R, Grattan CE. Lack of response of severe steroid-dependent chronic urticaria to rituximab. Clin Exp Dermatol 2007; 32:333-334.
42. Wilson LH, Eliason MJ, Leiferman KM, et al. Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. J Am Acad Dermatol 2009; 64:1221-1222.
43. Schultz-Larsen F, Hanifin J. Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002; 22:1-24.
44. Rudzki E, Samochocki Z, Litewska D, et al. Clinical features of atopic dermatitis and a family history of atopy. Allergy 1991; 46:125-128.
45. Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 2013; 68:498-506.
46. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol 2014. [Epub ahead of print]
47. Novak N, Simon D. Atopic dermatitis-from new pathophysiologic insights to individualized therapy. Allergy 2011; 66:830-839.
48. Bieber T. Atopic dermatitis: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012; 67:1475-1482.
49. Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006; 55:168-170.
50. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54:68-72.
51. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005; 53:338-340.
52. Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebocontrolled and double blind pilot study. J Dtsch Dermatol Ges 2010; 8:990-998.
53. Kim DH, Park KY, Kim BJ, et al. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 2013; 38:446-450.
54. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120:1223-1225.
55. Lim A, Luderschmidt S, Weidinger A, et al. The IgE repertoire in PBMCs of atopic patients is characterized by individual rearrangements without VH bias. J Allergy Clin Immunol 2007; 120:696-706.
56. Velling P, Skowasch D, Pabst S, et al. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res 2011; 16:407-410.
57. Hotze M, Baurecht H, Rodriguez E, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2014; 69:132-135.
58. Toledo F, Silvestre JF, Munoz C. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. J Eur Acad Dermatol Venereol 2012; 26:1325-1327.
59. Simon D, Hosli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008; 121:122-128.
60. Sediva A, Kayserova J, Vernerova E, et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008; 121:1515-1516.
61. Sánchez-Ramón S, Eguíluz-Gracia I, Rodríguez-Mazariego ME, et al. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 2013; 23:190-196.
62. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60:693-696.
63. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 52:522-526.
64. Navarini AA, French LE, Hofbauer GF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011; 128:1128-1130.
65. Ohsawa Y, Hirasawa N. The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via antipruritic and anti-inflammatory effects in NC/Nga mice. Allergy 2012; 67:1014-1022.
66. Jalilian C, Jevtic A. The management of toxic epidermal necrolysis. Australas J Dermatol 2012; 53:165-171.